Marinus Pharmaceuticals

Yahoo Finance • last year

Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference

RADNOR, Pa., November 14, 2023--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunste... Full story

Yahoo Finance • last year

Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

RADNOR, Pa., May 17, 2023--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah... Full story

Yahoo Finance • 2 years ago

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

ZTALMY® (ganaxolone) first quarter U.S. net product revenue of $3.3 million Now planning to conduct an interim analysis for the Phase 3 refractory status epilepticus trial in the second half of 2023 CHMP opinion for ZTALMY in CDKL5 deficie... Full story

Yahoo Finance • 2 years ago

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., April 06, 2023--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducemen... Full story

Yahoo Finance • 2 years ago

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

ZTALMY® U.S. net product revenue of $2.3 million for the fourth quarter of 2022 and $2.9 million for the fiscal year ended December 31, 2022 Company expects ZTALMY U.S. net product revenues of between $15 million and $17 million for the fi... Full story

Yahoo Finance • 2 years ago

Marinus to sell rare-disease voucher to Novo Nordisk for $110 million

Shares of Marinus Pharmaceuticals Inc. gained 7.9% in premarket trading on Thursday after the company said it plans to sell its Rare Pediatric Disease Priority Review Voucher for $110 million to Novo Nordisk . Marinus CFO Steven Pfanstiel... Full story

Yahoo Finance • 2 years ago

Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus

RADNOR, Pa., June 08, 2022--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has amended the... Full story

Yahoo Finance • 2 years ago

2 “Strong Buy” Penny Stocks That Could Rally All the Way to $30 (Or More)

There are two sides to every coin. For penny stocks, or tickers that trade for less than $5 per share, this rings especially true. As some of the most divisive names on the Street, they are either met with resounding praise or forceful dis... Full story

Yahoo Finance • 3 years ago

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

ZTALMY® (ganaxolone) U.S. commercial launch on track for July 2022 Phase 3 RAISE trial in refractory status epilepticus continues to advance with resumption of screening and recruitment; data readout expected second half 2023 Site activati... Full story